3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
38
Thoracic
6
CNS
4
Other solid neoplasm
3
Sarcoma
2
Head & Neck
2
Gastrointestinal
2
Endocrine
2
NET
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Ovarian Neoplasms
388
Endometrial Neoplasms
221
Uterine Cervical Neoplasms
217
Breast Neoplasms
115
Fallopian Tube Neoplasms
105
Colorectal Neoplasms
91
Carcinoma, Non-Small-Cell Lung
83
Neoplasms
70
Pancreatic Neoplasms
63
Stomach Neoplasms
57
Neoplasm Metastasis
54
Prostatic Neoplasms
52
Lung Neoplasms
49
Melanoma
46
Carcinoma, Ovarian Epithelial
44
Triple Negative Breast Neoplasms
41
Squamous Cell Carcinoma of Head and Neck
37
Esophageal Neoplasms
37
Carcinoma, Renal Cell
37
Colonic Neoplasms
33
Urinary Bladder Neoplasms
31
Peritoneal Neoplasms
30
Uterine Neoplasms
29
Head and Neck Neoplasms
29
Carcinoma, Hepatocellular
28
Vulvar Neoplasms
27
Small Cell Lung Carcinoma
25
Carcinoma, Transitional Cell
25
Uterine Cervical Dysplasia
22
Sarcoma
19
Interventions
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Gynecologic
×
90 days
×
Clear all
NCT03686124
2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2
Recruiting
375 enrolled